Promimic
27.1
SEK
+1.5 %
PRO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+1.5%
-20.99%
-20.29%
-20.06%
-17.13%
-12.58%
-
-
+66.44%
promimic.com
Promimic specializes in biotechnology. The company conducts research and development in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The main operations are in Europe and America, where research and development are conducted in-house but also through partners.
Revenue
37.07M
EBIT %
-24.6 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PRO
Daily low / high price
27.1 / 27.9
SEK
Market cap
511.98M SEK
Turnover
58.7K SEK
Volume
2.1K
Financial calendar
Annual report
25.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
K-Svets Venture AB | 38.7 % | 38.7 % |
KDev Investments AB | 12.5 % | 12.5 % |
Chalmers Ventures AB | 6.6 % | 6.6 % |
Riepen LLC | 5.6 % | 5.6 % |
Andra AP-fonden | 5.1 % | 5.1 % |
Swedbank Robur Ny Teknik | 3.3 % | 3.3 % |
Avanza | 3.1 % | 3.1 % |
Firma Andersson och Kjellin AB | 2.3 % | 2.3 % |
Per Kjellin | 2.0 % | 2.0 % |
Martin Andersson | 2.0 % | 2.0 % |